FDA investigates possible Vytorin link to cancer
August 23, 2008(AP) -- Federal drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer.
Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .
Similar stories from PHYSorg:
Trials find no benefits of Zetia
Jan 15, 2008 |
3.6 / 5 (12) |
0
FDA questions safety of Glaxo kidney cancer drug
Oct 01, 2009 |
not rated yet |
0
FDA confirms benefits of Crestor in more patients
2 hours ago |
not rated yet |
0
FDA: Arthritis drugs pose cancer risk to children
Aug 04, 2009 |
not rated yet |
1
Anti-psychotic drugs could help fight cancer
Aug 12, 2009 |
4.8 / 5 (4) |
1



The known problems with statin therapy and the severe disability, organ failure and deaths they cause should be sufficient to limit sales, but they apparently do not limit sales.
Of course, the advice in the article is to keep taking statins.